Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT03484923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: PDR001
DRUG: LAG525
DRUG: INC280
DRUG: ACZ885
DRUG: LEE011

Sponsor

Novartis Pharmaceuticals